Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $41.44.

ARWR has been the subject of several recent analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Piper Sandler reduced their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Finally, B. Riley reiterated a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the sale, the insider now directly owns 272,122 shares of the company's stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the sale, the chief executive officer now directly owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. The trade was a 3.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 280,765 shares of company stock valued at $5,227,313 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 11.5% in the 3rd quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company's stock valued at $2,401,000 after acquiring an additional 12,706 shares during the last quarter. Intech Investment Management LLC purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $659,000. Erste Asset Management GmbH acquired a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $924,000. Geode Capital Management LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock worth $57,426,000 after purchasing an additional 26,171 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock worth $123,083,000 after purchasing an additional 516,569 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Up 1.4 %

Arrowhead Pharmaceuticals stock traded up $0.24 during trading on Friday, reaching $17.35. The stock had a trading volume of 1,427,421 shares, compared to its average volume of 2,022,374. Arrowhead Pharmaceuticals has a 52-week low of $16.57 and a 52-week high of $35.80. The business has a 50 day moving average price of $19.51 and a 200 day moving average price of $20.63. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market cap of $2.19 billion, a PE ratio of -3.36 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.